Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK: A Chronic Kidney Disease Markov Model

By Nuijten Mark  

Clinical Drug Investigation, Vol. 30, Iss. 8, 2010-08 ,pp. : 545-557

Adis International

Access to resources Recommend Favorite

Management of Secondary Hyperparathyroidism in the Elderly Patient with Chronic Kidney Disease

By Cozzolino Mario   Gallieni Maurizio   Pasho Sabina   Fallabrino Giuditta   Ciceri Paola   >   Olivi Laura   Brancaccio Diego  

Drugs & Aging, Vol. 26, Iss. 6, 2009-06 ,pp. : 457-468

Adis International

Access to resources Recommend Favorite

Safety and tolerability of paricalcitol in patients with chronic kidney disease

By Dyer Christopher A  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 717-728

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis

By  

Hemodialysis International, Vol. 20, Iss. 4, 2016-10 ,pp. : 589-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hyperparathyroidism in chronic kidney disease: complexities within the commonplace

By Cai Michael M   McMahon Lawrence P   Smith Edward R   Williams David S   Holt Stephen G  

Clinical Medicine, Vol. 12, Iss. 4, 2012-08 ,pp. : 333-337

Royal College Of Physicians

Access to resources Recommend Favorite